Imfinzi (durvalumab) - AstraZeneca
Tecentriq (atezolizumab) - Roche
Opdivo (nivolumab) - BMS
Bavencio (avelumab) - EMD Serono
Avastin (bevacizumab) - Roche
Tevimbra (tislelizumab) - BeiGene
Libtayo (cemiplimab-rwlc) - Regeneron
http://www.ncbi.nlm.nih.gov/pubmed/38745663
 
Hewei Xiao; Huijuan Li; Xiaoyu Chen; Xueyan Liang; Yan Li
 
May 15, 2024
 
Next